BioLife Solutions (BLFS) AI Stock Analysis

• Market Cap: $937.02M
• Dividend Yield: N/A
• Average Volume (3M): 363.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: -18.82%
• EPS Growth: 92.56%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.04
• Shares Outstanding: 48,300,000
• 10 Day Avg. Volume: 392,925
• 30 Day Avg. Volume: 363,004
• PEG Ratio: 2.20
• Price to Book (P/B): 3.10
• Price to Sales (P/S): 12.00
• P/FCF Ratio: 108.55
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 9.58
• Enterprise Value/Gross Profit: 14.84
• Enterprise Value/Ebitda: -114.95
• 1Y Price Target: $33.20
• Price Target Upside: 71.13% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 0.14
• Revenue Forecast (FY): $112.85M

• Rating: 64 Neutral
• Price Target: $19.50 ▲(0.52% Upside)
• Action: Reiterated Date: 03/04/26
• Date: Action: Reiterated 03/04/26

BLFS scores in the mid-range driven by improving fundamentals (growth, strong balance sheet, and positive free cash flow) and constructive 2026 guidance pointing to GAAP profitability. This is tempered by weak technical trend signals and a negative P/E that reflects still-unproven GAAP earnings durability.

Positive Factors

Strong balance sheet & low leverage

Very low leverage and sizable cash provide durable financial flexibility. With $120M+ in cash and minimal debt, BioLife can fund R&D, scale commercial operations, pursue tuck-in M&A, and weather demand variability without near-term refinancing risk, supporting multi‑year execution.

Improved cash generation

A return to positive operating and free cash flow signals a structural improvement in cash conversion. Consistent positive FCF enables self-funding of growth initiatives, reduces dependency on external capital, and supports sustained investment in commercialization and product development.

Market leadership in BPM consumables

Deep adoption across approved therapies, high trial penetration, and durable specification in workflows create sticky, recurring consumable revenue. This entrenched competitive position supports long-term demand, pricing power, and cross-sell potential as cell & gene therapies scale commercially.

Negative Factors

Customer concentration risk

High revenue concentration in a small customer cohort elevates downside risk: lost volume or pricing pressure from a few large buyers would materially impact sales and utilization. This concentration limits diversification benefits and increases revenue volatility over a multi‑quarter horizon.

Bag-yield issues & margin headwind

Operational yield problems and a needed customer notification/sell-through period impose a sustained gross‑margin drag through remediation. Even with solutions identified, inventory and mix effects will pressure margins for multiple quarters, challenging margin sustainability near term.

Persistent GAAP losses; negative ROE

Despite improving adjusted metrics, ongoing GAAP losses and negative ROE indicate the capital base has not yet produced consistent profitable returns. This structural profitability gap raises execution risk and prolongs the timeline for sustained shareholder value creation absent durable GAAP earnings.

BioLife Solutions Business Overview & Revenue Model

Company Description

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

How the Company Makes Money

BioLife Solutions makes money primarily by selling biopreservation products and by providing cold-chain/cryogenic services to biopharma and cell & gene therapy customers. Key revenue streams include: (1) Product revenue from the sale of proprietary biopreservation media and related consumables used by customers to store and transport cells and other biological materials under controlled conditions; these sales are typically recurring as customers consume product in R&D, clinical, and commercial workflows. (2) Service revenue from cryogenic storage and related handling/processing services, where customers pay fees for storing biological materials and for associated operational services (e.g., intake, inventory management, withdrawals/shipments, and other value-added handling activities). (3) Logistics-related revenue from providing temperature-controlled shipping and cold-chain solutions for sensitive materials, where customers pay for shipment services and any related packaging/handling offerings. Information on specific pricing, customer concentration, or named significant partnerships contributing to earnings: null.

BioLife Solutions Financial Statement Overview

Summary

Financials are improving with strong 2025 revenue growth (~30%), healthy gross margins (~65%), very low leverage (debt-to-equity ~0.03), and a rebound to positive operating/free cash flow (~$20M). The key offset is persistent GAAP net losses and historical volatility, which still limit the score despite the clear trajectory.

Income Statement

Revenue growth is strong in 2025 (up ~30% year over year) and gross margins remain healthy (~65%), showing solid pricing power and product economics. However, profitability is still the key gap: net losses persist (about -13% net margin in 2025), and results have been volatile over the period (large losses in 2022–2023). Overall, the income statement shows improving operations and scale, but not yet consistent bottom-line profitability.

Balance Sheet

The balance sheet is a clear strength with very low leverage: debt is modest relative to equity (debt-to-equity ~0.03 in 2025, improved from ~0.09 in 2024). Equity remains large versus total assets, providing financial flexibility. The main weakness is that returns on equity are still negative due to ongoing losses, meaning the capital base is not yet generating positive earnings.

Cash Flow

Cash generation has improved meaningfully: operating cash flow and free cash flow are both positive in 2025 (~$20M), with very strong free cash flow growth versus 2024. This is a notable turnaround from negative operating and free cash flow in 2022–2023. The key concern is consistency—cash flow has been choppy historically—and profitability is still negative even as cash flow turns positive.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	96.21M	82.25M	75.86M	76.24M	119.16M
Gross Profit	62.12M	53.67M	46.75M	46.91M	28.85M
EBITDA	-9.38M	1.53M	-45.24M	-124.18M	-16.65M
Net Income	-12.13M	-20.18M	-66.43M	-139.81M	-8.91M
Balance Sheet
Total Assets	405.88M	399.49M	412.71M	450.23M	552.60M
Cash, Cash Equivalents and Short-Term Investments	88.93M	104.58M	44.18M	62.70M	69.87M
Total Debt	17.90M	30.17M	33.83M	43.71M	26.88M
Total Liabilities	34.00M	50.58M	75.05M	86.04M	76.24M
Stockholders Equity	371.89M	348.91M	337.66M	364.19M	480.75M
Cash Flow
Free Cash Flow	10.64M	5.20M	-18.88M	-18.87M	-13.22M
Operating Cash Flow	20.11M	8.43M	-12.50M	-8.49M	-4.84M
Investing Cash Flow	-71.54M	58.30M	17.84M	-58.12M	-12.64M
Financing Cash Flow	-10.92M	-6.78M	10.59M	16.32M	-2.78M

BioLife Solutions Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 19.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Negative. The current price of 19.4 is below the 20-day moving average (MA) of 20.99, below the 50-day MA of 22.64, and below the 200-day MA of 24.06, indicating a bearish trend. The MACD of -1.16 indicates Positive momentum. The RSI at 39.67 is Neutral, neither overbought nor oversold. The STOCH value of 35.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLFS.

BioLife Solutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BLFS	64 Neutral	$937.02M	-95.19	-3.40%	―	-18.82%	92.56%
AZTA	56 Neutral	$1.01B	-24.75	-3.39%	―	-9.49%	58.97%
PLSE	56 Neutral	$1.52B	-12.71	-73.46%	―	―	-40.63%
KMTS	52 Neutral	$1.23B	-10.73	-189.09%	―	62.06%	-41.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STAA	46 Neutral	$883.80M	-14.54	-23.24%	―	-32.42%	-540.37%
SMTI	42 Neutral	$175.32M	-2.26	-127.51%	―	30.55%	-340.19%

BioLife Solutions Corporate Events

BioLife Solutions Highlights Growth and Strategic Refocus in Presentation

On March 2, 2026 BioLife Solutions issued an investor presentation outlining its current positioning as a leading provider of biopreservation media and cell processing tools for cell-based therapies, highlighting its mission to protect cell integrity and enable development and delivery of advanced treatments. The February 2026 presentation detailed 2025 pro forma results, including $96 million in revenue, 29% organic growth, a 26% adjusted EBITDA margin and a 65% gross margin, with revenue largely driven by consumable biopreservation media specified in more than 950 global clinical trials and numerous commercially approved therapies.

The materials also emphasized BioLife’s 28-year innovation track, from early biopreservation work to its role in supporting approved cell-based therapies such as Yescarta, and chronicled a recent strategic pivot away from lower-margin storage, services and freezer operations toward higher-growth cell processing consumables. Management presented the divestitures of cold chain storage and freezer assets and the acquisitions of PanTHERA and a stake in Pluristyx as having improved growth durability, profitability and net cash, reinforcing BioLife’s positioning as an industry leader in tools that underpin ex vivo cell and gene therapy workflows.

The most recent analyst rating on (BLFS) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.

BioLife Solutions announces planned retirement of key executive

On January 8, 2026, BioLife Solutions, Inc. announced that its Chief Quality and Operations Officer, Karen Foster, will retire from her role effective March 31, 2026. The company emphasized that her retirement is not due to any disagreement regarding its operations, policies, or practices, and expressed appreciation for her contributions, suggesting a planned leadership transition with no indicated disruption to ongoing business activities.

The most recent analyst rating on (BLFS) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on BioLife Solutions stock, see the BLFS Stock Forecast page.